In:
Disease Markers, Hindawi Limited, Vol. 2017 ( 2017), p. 1-8
Abstract:
FOXP3 genetic polymorphisms have been associated with cancer development and prognosis. In this context, the present study aimed to evaluate the g.10403A 〉 G (rs2232365) polymorphisms and g.8048A 〉 C (rs3761548), in aggressive breast cancer (BC) subtypes, including, Luminal B HER2+ (LB), HER2-enriched (HER2+), and triple-negative (TN). Polymerase chain reaction followed by enzymatic restriction was performed to genotyping 117 BC samples and 300 controls. A significant association of AA genotype (g.10403A 〉 G) in relation to BC susceptibility (OR = 1.93; 95% CI = 1.01–3.66; p = 0.046 ) was observed. The GG (g.10403A 〉 G) genotype was correlated with higher proliferation index (Ki-67) in HER2+ subtype ( τ = 0.47; p = 0.019 ) and advanced TNM staging in TN ( τ = 0.23; p = 0.032 ). A correlation of AA genotype (g.8048A 〉 C) with higher Ki-67 ( τ = −0.47; p = 0.018 ) and lower histological grade ( τ = 0.39; p = 0.026 ) in HER2+ was also found. GA haplotype was correlated with lower histological grade ( τ = −0.15; p = 0.009 ) and higher Ki-67 ( τ = 0.43; p = 0.036 ) in HER2+ and advanced staging in TN ( τ = 0.29; p = 0.044 ). On the other hand, AC haplotype was correlated with lower Ki-67 ( τ = −0.54; p = 0.005 ) and staging ( τ = −0.29; p = 0.027 ) in HER2+ and TN respectively. Results showed that FOXP3 influence regarding clinical outcome depends greatly on the BC subtype and indicated this transcription factor as a promising marker in aggressive BC subtypes.
Type of Medium:
Online Resource
ISSN:
0278-0240
,
1875-8630
DOI:
10.1155/2017/6359603
Language:
English
Publisher:
Hindawi Limited
Publication Date:
2017
detail.hit.zdb_id:
2033253-1
Permalink